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recovery; post-event health states represented chronic impact. UK general popula-
tion respondents valued the health states in time trade-off tasks with time horizons 
of one year for acute states and ten years for chronic states. Results: A total of 200 
participants completed interviews (55% female; mean age = 46.6y). Among acute 
health states, stroke had the lowest utility (0.33), followed by heart failure (0.60) and 
ACS (0.67). Utility scores for chronic health states followed the same pattern: stroke 
(0.52), heart failure (0.57), and ACS (0.82). For stroke and ACS, acute utilities were 
significantly lower than utilities for chronic post-event (difference = 0.20 and 0.15, 
respectively; both p < 0.0001). ConClusions: Results add to previously published 
utilities for cardiovascular events by distinguishing between chronic post-event 
health states and acute health states that include the event and its immediate 
impact. Findings suggest that acute and chronic impact should be considered when 
selecting scores for use in cost-utility models. Thus, the current utilities provide a 
unique option that may be used to represent the acute and chronic impact of car-
diovascular conditions in economic models comparing treatments that may delay 
or prevent the onset of cardiovascular events.
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objeCtives: We aimed to understand the short-term impact on quality of life 
associated with Non VKA Oral AntiCoagulants (NOACs) use in patients with AF. We 
obtained baseline (BL) and follow-up (FU) data on the health state of AF patients 
under everyday practice conditions in the PREvention oF thromboembolic events 
– European Registry in Atrial Fibrillation (PREFER in AF). Methods: PREFER in AF 
documents AF patients in terms of clinical characteristics, management, qual-
ity of life and other outcome parameters. The EuroQol EQ-5D-5L descriptive sys-
tem and visual analogue scale (VAS) were applied in PREFER in AF at BL and FU 
to obtain patient-reported generic health-related quality of life information and 
utility weights. Results: Of the 6390 AF patients at follow-up 1895 (29.7%) had 
paroxysmal, 1533 (24.0%) persistent, 474 (7.4%) long-standing persistent, and 2488 
(38.9%) permanent AF. Comorbidities were highly prevalent. 3344 AF patients (61.1% 
males, mean age 71.7 ± 9.85 years) provided EQ-5D-5L data both at BL and 12-month 
FU. On the VAS (range 0-100), the mean score at FU was 68.8 ±18.1 points, with 
no major differences between patients on NOACs (68.3), VKAs (68.9), AP (70.1), or 
VKA+AP (71.7), respectively. All scores improved from baseline from 0.36 in patients 
on VKA to 1.77 for those on AP. The overall utility index at FU was 0.80 ±0.21. At FU 
the 409 patients on NOACs had a utility score of 0.79 (change from BL, -0.01), the 
1789 patients VKAs 0.80 (-0.01), the 237 patients on AP 0.81 (+0.01), the 151 patients 
on VKA and AP 0.80 (-0.01) and the 749 patients receiving neither VKAs nor AP 
0.80 (0.00). ConClusions: Patients with AF present with reduced self-reported 
quality of life compared to the general population. Patients receiving NOACs had 
similar quality of life both at baseline and after 12-month FU, when compared to 
alternative medications.
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objeCtives: Non-VKA oral anticoagulants (NOAC), which do not need routine 
monitoring, have the potential to improve the quality of life (QoL) in patients on 
long-term treatment for venous thromboembolism (VTE). We aimed to obtain 
contemporary data on the health state of patients with VTE under daily practice 
conditions. Methods: PREFER in VTE is a non-interventional study in 7 countries 
(France, Germany, Austria, Switzerland, Italy, Spain, UK) that prospectively docu-
ments patients after an event of acute deep venous thrombosis (DVT) or pulmo-
nary embolism (PE) in terms of clinical characteristics, management, quality of life 
and other outcome parameters. The EuroQol EQ-5D-5L consists of the 5-dimension 
descriptive system used to derive utility scores and the visual analogue scale (VAS), 
measuring self-rated health (scale 0-100). Results: A total of 2790 patients with 
acute VTE at baseline (BL: 1640 DVT, 1150 PE ±DVT) and 723 patients at an interim 
analysis at 6 months (443 DVT and 280 PE ±DVT) completed the EQ-5D-5L. On the 
EQ VAS for current health state, the mean score at 6 months was 73.8 points (change 
from BL +10.9), with similar values in DVT patients (74.6, change from BL +9.8) 
compared to PE patients (72.4, change from BL +12.4). Between BL and 6-month 
follow-up, index values increased in all medication classes (heparin only: 0.66 to 
0.75; heparin/VKA: 0.70 to 0.84; NOAC: 0.73 to 0.87). Overall the index value increased 
from 0.69 to 0.83 (DVT: 0.71 to 0.85, PE: 0.67 to 0.81). ConClusions: Under clinical 
practice conditions, patients on NOAC and heparin/VKA had larger increases in their 
health state scores than those on heparin only. This generic QoL tool detected only 
small differences between treatment options. Six months after the event, patients 
with DVT had similar self-reported QoL on the VAS compared to patients with PE, 
and patients with DVT had somewhat higher utility values.
questions that presented a pair of virtual patients who were prescribed different 
treatments defined by: reduction in the risks of nonfatal MI and fatal MI, treat-
ment-related risk of serious infection, mode and frequency of administration, and 
monthly medication cost. Half of the choice questions asked respondents to select 
the treatment to which they would most likely be nonadherent. The other half asked 
respondents to state which of two virtual patients was better off after learning how 
adherent each was to each medication. Limited dependent-variable models were 
used to estimate weights indicating the impact of treatment and respondent char-
acteristics on stated-adherence and quantifying the stated impact of nonadherence 
on respondents’ well-being. Results: Results indicated that reductions in the risk 
of a nonfatal MI had the largest effect on stated adherence, followed by medication 
cost, the risk of serious infection, and lastly mode and frequency of administration. 
Results also show that reductions in compliance had a significant impact on the 
perceived overall benefits of prophylactic treatments. ConClusions: We find that 
both clinical and nonclinical factors can impact treatment adherence, suggesting 
that the flexibility to include a variety of factors with SP models can be useful in 
understanding patient compliance.
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objeCtives: The aim of the study was to assessment of compliance by adolescents 
in the field of pharmacological and non-pharmacological methods of hyperten-
sion treatment. Methods: The study included 62 patients (20 women, 42 men) 
diagnosed with hypertension and treated in specialist health care facilities. As 
a research tool was used questionnaire prepared on the basis of recent litera-
ture. Results: The vast majority of respondents (72,7%) declared that regularly taking 
antihypertensive drugs. The proportion of patients regularly taking antihypertensive 
drugs was higher in patients treated with monotherapy than polytherapy (48,5% vs 
24,2%). Among the methods of non-pharmacological treatment of hypertension the 
most accepted lifestyle change in the study population was smoking cessation (83,8% 
of respondents) and reduction of salt consumption (64,5% of respondents), and the 
least acceptable lifestyle change was to maintain proper body weight by eating a low 
calorie diet (30,6% of respondents). ConClusions: Adolescents with hypertension 
in varying degrees adhere to a medical recommendations related to the hypertension 
treatment. From the available literature data indicate that the current effective way 
to improve cooperation with the patient’s is education.
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objeCtives: Previous research has shown the impact of chronic heart failure (CHF) 
on health-related quality of life (HRQL). Less is known regarding the impact of 
reduced ejection fraction (HFrEF) on HRQL. The aim of this study was to elicit utility 
values for CHF with HFrEF or preserved ejection fraction (HFpEF) by New York Heart 
Association (NYHA) classification system in the UK. In addition, utility values for 
events such as stroke, myocardial infarction (MI) and chronic kidney disease (CKD) 
were estimated. Methods: Health states were developed from concept elicitation 
interviews with CHF patients (N= 10) and cardiologists (N= 5). Draft health states 
were validated in cognitive debrief interviews with different patients (N= 5) and 
cardiologists (N= 4) and finalised with scientific input from experts. The resulting 
health states (n = 10) were piloted with general public to check understanding. 
General public participants (n= 100) completed background questions and rated each 
state using visual analogue scale and time trade-off (TTO) assessments (with lead 
time method for states worse than dead). Results: The mean TTO utility for HF-rEF 
ranged between 0.86 (SD= 0.19) (NYHA class II); 0.60 (SD= 0.23) (NYHA III) to 0.28 
(SD= 0.41) (NYHA IV). Equivalent values for HF-pEF were 0.83 (SD= 0.24) (NYHA II); 
0.55 (SD= 0.28) (NYHA III) to 0.27 (SD= 0.35) (class IV) respectively. Other values 
were post hospitalisation after stroke (mean= 0.30, SD= 0.43); post MI (mean= 0.45, 
SD= 0.37) and CKD (mean= 0.78, SD= 0.21). Post-hospitalisation states captured a 
period of upto three months after the event. ConClusions: This study shows the 
effect that NYHA class has on HRQL for people with CHF in the UK. The findings 
showed that HFrEF and HFpEF were very similar. Participants considered events such 
as recovery from stroke to have significant impact on HRQL. These are important 
data to consider in evaluating outcomes of treatments and should be reflected in 
cost effectiveness models in CHF where relevant.
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objeCtives: Cost-utility models are frequently conducted to compare treatments 
intended to prevent or delay cardiovascular events. Most published utilities repre-
sent post-event health states without incorporating the disutility of the event or 
reporting the time between the event and utility assessment. Therefore, the objec-
tive of this study was to estimate health state utilities representing cardiovascular 
conditions while distinguishing between acute impact including the cardiovascular 
event and the chronic post-event impact. Methods: Health states were drafted 
and refined based on literature review, clinician interviews, and a pilot study. Three 
cardiovascular conditions were described: stroke, acute coronary syndrome (ACS), 
and heart failure. One-year acute health states represented the event and gradual 
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aggressive therapies such as complex devices or ultrafiltration, as well as enabling 
an enriched end of life experience for those beyond such therapies. Enabling end 
stage patients to die in their location of choice would also release considerable 
resources at the same time.
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objeCtives: We wanted to compare the patient satisfaction and compliance 
between a hospital with a trained clinical psychologist, acting as a mediator 
between physicians and patients and a hospital without one. Methods: The 
comparison was done between two identical cardiac hospitals, which belong 
to the same network of cardiac facilities, for a period of six months. At each 
hospital, 200 patients were included. The patient characteristics, numbers and 
patient flow were comparable; the facilities were identical as level of comfort 
and staff training. To measure the patient satisfaction we used a questionnaire. 
The level of attendance of control visits after discharge we measured with the 
hospital registry. How many of the 200 patients stick to the discharge therapy 
after 3 and after 6 months after discharge, we measured with the out-patient cen-
tre registry and by telephone interviews. Results: In each hospital 200 patients 
were included and followed-up. For the hospital without clinical psychologist, 
patient satisfaction was 79% excellent marks (n= 158), control visits attendance 
was 42% (n= 84), patient compliance was 72% (n= 144) on the 3rd and 65% (n= 130) 
on the 6th month after discharge. For the hospital with a clinical psychologist, 
patient satisfaction was 97% excellent marks (n= 194), control visits attendance 
was 78% (n= 156), patient compliance was 96% (n= 192) on the 3rd and 89% (n= 178) 
on the 6th month after discharge. With the help of a trained clinical psychologist, 
we witnessed the following differences: 18% improvement in patient satisfac-
tion, 36% better attendance to control visits, 24% more compliant patients for 
both the 3rd and 6th month after discharge. ConClusions: Trained clinical 
psychologists may play the role of a mediator and close the communication gap 
between physicians and patients and lead to improved patient satisfaction and 
compliance.
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objeCtives: We wanted to establish the gap between physicians’ and patients’ 
understanding of patient needs in a hospital setting. Methods: The study was 
run in the four of the Bulgarian Cardiac Institute clinics. We used questionnaires 
and within a period of two months, first we asked 30 physicians and 50 patients 
about what patient needs are according to their understanding. Based on the 
answers we defined 10 categories for each of the two groups. Then we asked 143 
physicians and 500 patients to define which category is most and least important 
for them by using the Maximum Difference Scaling technique. Results: Courtesy, 
after discharge recommendations and information about the discharge drugs were 
the top three most important patient needs according to the patients. Life-saving 
activities, improvement of quality of life and improve the longevity were the top 
three most important patient needs according to the physicians. ConClusions: 
There is a tremendous gap between patients’ and physicians’ perceptions of 
patient needs. It is very hard for the hospitals to increase patient satisfaction 
relying on medical services only. Further research is needed to find ways to close 
that gap.
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objeCtives: Given ethnic variation in attitudes toward hypertension (Ford 2010; 
Lewis 2010), study objectives are to determine 1) patient preferences concerning med-
ication use as revealed by responses to Beliefs about Medicines Questionnaire (BMQ, 
Horne 1999) in an urban black population with hypertension (HTN) and 2) if these 
preferences were influenced by experiences with parents/friends HTN diagnoses.  
Methods: After approval from Northeastern University’s Institutional Review 
Board, coded clinic appointment schedules were used to identify patients sched-
uled for routine HTN follow-up appointment at a Boston inner-city community 
health center. Researchers screened for eligibility (English speaking, black eth-
nicity, taking anti-hypertensive medication), described the study, and requested 
informed consent. Patients agreeing to participate and completing background 
questions and the hypertension-specific Beliefs about Medicines questionnaire 
(BMQ: 18 items, 5 levels, strongly agree-strongly disagree) received a $10 CVS-
provided gift card. Results: 189 patients were approached. 94 (49.7%) completed 
the questionnaire, 11.6% declined, and 38.6% didn’t meet criteria, e.g., didn’t speak 
English or had previously completed the BMQ. Patients averaged 55.6yo, 67% 
female. Overall BMQ factor scores were: Specific Necessity (SN), 3.41 ±0.83; Specific 
Concerns (SC), 2.82 ±0.8; General Overuse (GO), 2.98 ±0.74 and General Harm (GH), 
2.54 ±0.72. Patients whose parent had a stroke had higher SN (p= 0.038) and lower 
GH scores (p= 0.042) than patients without that prior experience. There was no dif-
ference in any factors as to whether parents or a friend did/didn’t have hyperten-
sion and whether a friend did/didn’t have a stroke. SC were lower in patients with 
higher educational level (p= 0.002). No statistical associations occurred between 
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objeCtives: While the independent influence of metabolic and cardiovascular 
diseases on either quality of life (QoL) or survival is well studied, the evidence on 
the combined burden in terms of quality adjusted life years (QALYs) is rather weak. 
Previous burden of disease studies mostly combined cross-sectional QoL data 
with mortality statistics from other data sources. However, due to strong model 
assumptions these studies might be limited in validity and accuracy. The goal of 
this study was to analyze the intermediate burden of diabetes in patients with 
previous myocardial infarction in terms of QALYs lost, by introducing a method 
capable to exploit primary longitudinal data sources of population-based stud-
ies. Methods: Data for this analysis were taken from the KORA-Acute Myocardial 
Infarction (AMI) Registry. QoL (Euro-Qol-5D-index, German tariff) of a subset of 
patients known to be alive was assessed through postal surveys in 2006 (n= 1022) 
and subsequently in 2011 (n= 716). Mortality was tracked by the routine surveil-
lance system of the AMI Registry. QALYs gained were calculated assuming a 
linear QoL change from baseline to follow-up. QoL trajectories of non-respond-
ers at follow-up and patients who died before follow-up were approximated by 
multiple imputation methods using the baseline QoL and covariate structure. 
Ordinary least square regression models were performed to quantify the QALYs 
and life years (LYs) lost over the mean observation time. Results: Over a mean 
observation time of 4 years, patients with diabetes lost 0.14 LYs (3.75 vs. 3.89, 
p< 0.01) and 0.36 QALYs (2.96 vs. 3.33, p< 0.01) more than patients without diabe-
tes. The QALY-gap was greatest for diabetic patients taking insulin (-0.66, p< 0.01). 
Sensitivity analyses showed that models were robust concerning model assump-
tions. ConClusions: The intermediate burden of diabetes for patients with CVD 
is substantial. Using individual-level data from population-based follow-up of 
studies is a valuable methodological extension to accurately quantify the burden 
of chronic conditions.
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objeCtives: A secondary analysis was carried out to test if differences existed in 
reported treatment satisfaction between non-valvular atrial fibrillation patients 
(NVAF) treated with vitamin K antagonist (VKA) anticoagulants and new oral anti-
coagulants (NOAC). Methods: A sample of 1318 patients was recruited at random 
in the FANTASIIA study, between June 2013 and March 2014, from which 77% were 
using VKA and 23% NOAC at least 6 months before inclusion. The specific treatment 
satisfaction instrument SAFUCA was used to test differences between groups. The 
SAFUCA questionnaire is composed by 7 dimensions and overall score, measured 
in a 0 (least satisfied), 100 (most satisfied) scale. Guyatt’s d was used to estimate 
effect size. Results: Mean age was 73.8 (SD= 9.4) years, and 42.5% were women. 
Patients using NOACs attained statistically significant higher values in the overall 
score and in all SAFUCA dimensions. Overall score effect size (NOAC vs VKA) was 
medium-small (79.91 vs 73.22, d= 0.43, p< 0.001). Small to large effect sizes were 
also found by dimension: Effectiveness (77.63 vs 72.70, d= 0.33, p< 0.01), Ease and 
Convenience (80.99 vs 73.72, d= 0.49, p< 0.001), INR Controls (62.35 vs 57.66, d= 0.32, 
p< 0.01), Impact on Daily Activities (90.08 vs 81.97, d= 0.55, p< 0.001), Medication 
Undesired Effects (86.20 vs 79.21, d= 0.47, p< 0.001), Satisfaction with Medical Care 
(80.30 vs 69.38, d= 0.74, p< 0.001), and Overall Satisfaction (80.30 vs 69.38, d= 0.74, 
p< 0.001). ConClusions: SAFUCA questionnaire was able to detect satisfaction 
differences between NVAF patients treated with NOAC and those treated with VKA, 
presenting medium effect size in most dimensions. This new evidences offer addi-
tional support to the questionnaire validity.
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objeCtives: Unplanned patient admissions to hospital with heart failure (HF) are 
on the increase due to an ageing population and increasing survival post coronary 
disease. Pre-discharge mortality is high, predictable and often occurs after many 
days stay for many patients and often without palliative care involvement, not 
aligned with guidance. Methods: We audited palliative care input to HF patients 
admitted to our hospital as the predominant condition and subsequently passing 
away, both before and after an awareness campaign, publishing barriers to end 
of life dialogues between patient and clinicians, demonstrating the early use of 
a Get With The Guidelines (GWTG) risk assessment tool to predict mortality and 
introduction of a daily HF nursing team service. Results: In 2009, amongst 57 HF 
patients the average time to death was 17.8 days, only 7% received any palliative 
input before death. The time to death in these patients correlated positively with the 
(GWTG) predictive score indicating that these deaths could have been anticipated 
and appropriate palliative involvement triggered. Data from 2010 to 2013 following 
these interventions (n= 99) showed a marked improvement with 44% of patients 
having palliative input before death. The average time to death in this group was 
comparable at 17.22 days. ConClusions: The care of HF patients and their families 
can be greatly improved with early mortality prediction, sensitive dialogues, routine 
involvement of HF teams both to enhance survival for patients who will benefit from 
